Table 1.
Patients’ characteristics (n = 82)
| CCRT (n = 54) | RT alone (n = 28) | p-value | |
|---|---|---|---|
| Age (yr) | |||
| 70–74 | 40 (74.1) | 12 (42.9) | 0.016b) |
| 75–79 | 11 (20.4) | 12 (42.2) | |
| ≥80 | 3 (5.5) | 4 (14.2) | |
| Gender | |||
| Male | 48 (88.9) | 25 (89.3) | 0.957a) |
| Female | 6 (11.1) | 3 (10.7) | |
| ECOG performance status | |||
| 0–1 | 19 (35.2) | 9 (32.1) | 0.783a) |
| 2–4 | 35 (64.8) | 19 (67.9) | |
| Charlson Comorbidity Index | |||
| 2–4 | 43 (79.6) | 20 (71.4) | 0.404a) |
| 5–8 | 11 (20.4) | 8 (28.6) | |
| Pre-RT BMI | |||
| <22 | 24 (44.4) | 16 (57.1) | 0.275a) |
| ≥22 | 30 (55.6) | 12 (42.9) | |
| History of smoking | |||
| Yes | 48 (88.9) | 25 (89.3) | 0.957a) |
| No | 6 (11.1) | 3 (10.7) | |
| Histology | |||
| ADC | 9 (16.7) | 7 (25.9) | 0.603a) |
| SqCC | 35 (64.8) | 17 (59.3) | |
| Others+ | 10 (18.5) | 4 (14.8) | |
| Stage | |||
| IIIA | 35 (64.8) | 21 (75.0) | 0.347a) |
| IIIB | 19 (35.2) | 7 (25.0) | |
| T stage | |||
| T1/T2 | 23 (42.6) | 12 (42.9) | 0.982a) |
| T3/T4 | 31 (57.4) | 16 (57.1) | |
| N stage | |||
| N0/N1 | 9 (16.7) | 5 (17.9) | 0.735a |
| N2 | 27 (50.0) | 16 (57.1) | |
| N3 | 18 (33.3) | 7 (25.0) | |
| Induction chemotherapy | |||
| Yes | 37 (68.5) | 14 (50.0) | 0.101a) |
| No | 17 (31.5) | 14 (50.0) | |
| Consolidation chemotherapy | |||
| Yes | 6 (11.1) | 6 (21.4) | 0.320a) |
| No | 48 (88.9) | 22 (78.6) | |
| Total dose (BED2) | 63.5 ± 5.0 (48.0–70.9) | 63.7 ± 3.6 (55.3–70.0) | 0.542c) |
| Weight loss ≥5% after RT | |||
| Yes | 17 (31.5) | 2 (7.1) | 0.031a) |
| No | 37 (68.5) | 26 (92.9) |
Values are presented as number (%) or mean ± standard deviation.
ECOG, Eastern Cooperative Oncology Group; RT, radiotherapy; BMI, body mass index; ADC, adenocarcinoma; SqCC, squamous cell carcinoma; Others+, large cell neuroendocrine carcinoma, poorly differentiated carcinoma; BED2, biologically effective dose at 2 Gy per fraction.
a)
Chi-square test,
b)
Fisher exact test, and
c)
Mann-Whitney U test.